Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
Open Access
- 15 November 2012
- journal article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 1 (1), 29
- https://doi.org/10.1186/2001-1326-1-29
Abstract
Rapamycin was discovered more than thirty years ago from a soil sample from the island of Rapa Nui. It was isolated from Streptomyces hygroscopicus and initial characterization focused on its antifungal activities. Subsequent characterization showed that it has immunosuppressive properties and has been used successfully to reduce organ rejection with kidney transplantation. Rapamycin has proven to be a versatile compound with several seemingly unrelated properties, including antifungal, immunosuppressive, and anticancer. The National Cancer Institute (NCI) Developmental Therapeutics Program demonstrated that rapamycin inhibited cell growth in tumor cell lines. These observations stimulated research to explore the underlying mechanism of anti-tumor activities. Cell growth inhibition involves binding to the mammalian Target of Rapamycin (mTOR). The mTOR signaling pathway is critical to cell growth, proliferation, and survival and rapamycin inhibits these hallmark processes of cancer. Binding of growth factors activates mTOR signaling, which in turn leads to downstream phosphorylation of protein kinases, e.g., p70S6 kinase and lipid kinases in the phosphorylation of phosphoinositides. Understanding of mTOR signaling provided the biological basis for targeted chemotherapeutics development, including several rapamycin analogues for treating breast and other cancers.Keywords
This publication has 45 references indexed in Scilit:
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO StudyJournal of Clinical Oncology, 2012
- Identification of TOR Signaling Complexes: More TORC for the Cell Growth EngineCell, 2002
- TOR Deficiency in C. elegans Causes Developmental Arrest and Intestinal Atrophy by Inhibition of mRNA TranslationCurrent Biology, 2002
- Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4EGenes & Development, 2002
- Expression and disruption of the Arabidopsis TOR (target of rapamycin) geneProceedings of the National Academy of Sciences of the United States of America, 2002
- Rapamycin's resurrection: a new way to target the cancer cell cycle.JNCI Journal of the National Cancer Institute, 2001
- The p70 S6 Kinase Integrates Nutrient and Growth Signals to Control Translational CapacityPublished by Springer Science and Business Media LLC ,2001
- A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and AktProceedings of the National Academy of Sciences of the United States of America, 2000
- Regulation of cellular growth by the Drosophila target of rapamycin dTORGenes & Development, 2000
- TOR, a Central Controller of Cell GrowthCell, 2000